Enara Bio

Recent Finacing

Series B

Recent Raise

$32.5M

Enara Bio operates the EDAPT platform to discover and validate Dark Antigens from non-coding genomic regions and develop TCR-directed immunotherapies using bioinformatics, immunopeptidomics, and RNA in situ hybridization.

Founded 2016

England, United Kingdom

51-100

Private

enarabio.com

Highlights

Focus Areas

Biotechnology

Health Care

Therapeutics

Recent Investors

Financials

$32.5M

Total Raised

1

Funding round

6

Investors

Team

Upgrade to view the team

See the team members at Enara Bio.